Nadine Tung, MD on A Phase II Study of Olaparib Monotherapy in Breast Cancer #ASCO2020 #ASCO @DanaFarber @Harvard

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.